---
title: "ppip preexposure prophylaxis hiv prevention"
year: 2023
month: 12
journal: "American Family Physician"
volume: "108"
issue: "12"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-12-ppip-preexposure-prophylaxis-hiv-prevention.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# ppip preexposure prophylaxis hiv prevention

                          Putting Prevention Into Practice
                                                   An Evidence-Based Approach

                               Preexposure Prophylaxis
                             to Prevent Acquisition of HIV
                            Howard Tracer, MD, Associate Scientific Director, U.S. Preventive Services
                                        Task Force Program, Agency for Healthcare Research and Quality
                      Nathan C. Lorei, MD, General Preventive Medicine Resident, Uniformed Services
                            University of the Health Sciences, Department of Preventive Medicine and Biostatistics


Case Study                                                                       Case Study Questions
A 28-year-old woman presents to a community health clinic                        1. Which one of the following best describes the U.S.
for sexually transmitted infection (STI) testing. She reports                    Preventive Services Task Force (USPSTF) recommendation
no chronic illnesses, illicit substance use, or symptoms at                      on PrEP to prevent acquisition of HIV?
this time. She has a history of gonorrhea, which was appro-                         l A. The USPSTF recommends that clinicians selec-
priately treated more than one year ago. She also received                               tively offer PrEP using effective antiretroviral
one dose of injectable cabotegravir at that time but discon-                             therapy to people who are at increased risk of HIV
                                                                                         acquisition.
tinued use due to discomfort with injections. She reports
having multiple new male sex partners since her last STI                            l B. The USPSTF recommends that clinicians pre-
check and engaging in oral, vaginal, and anal intercourse                                scribe PrEP using effective antiretroviral therapy
                                                                                         to people who are at increased risk of HIV acqui-
with condom use in three-fourths of all encounters. After
                                                                                         sition to decrease the risk of acquiring HIV.
further discussion, the patient says she has been engaging
                                                                                    l C. The USPSTF recommends against prescribing
in transactional sex and does not know her partners’ sexual
                                                                                         PrEP to older adults because they are not at
histories. She requests HIV screening and preexposure pro-                               increased risk of HIV acquisition.
phylaxis (PrEP).
                                                                                    l D. The USPSTF concludes that the evidence is
                                                                                         insufficient to assess the balance of benefits and
                                                                                         harms of prescribing PrEP to decrease the risk of
                                                                                         acquiring HIV.
                                                                                    l E. The USPSTF recommends against prescrib-
                                                                                         ing PrEP to decrease the risk of acquiring HIV
                                                                                         because the harms outweigh the benefits.

                                                                                 2. According to the USPSTF, which one of the following
  See related USPSTF Clinical Summary in the online version                      factors makes this patient a candidate for PrEP?
                                                                                    l A. She regularly receives STI screenings.
  of this issue.

                                                                                    l B. She has requested screening for HIV.
  This PPIP quiz is based on the recommendations of the
  USPSTF. More information is available in the USPSTF Rec-
  ommendation Statement and supporting documents on                                 l C. She has a history of gonorrhea from more than
  the USPSTF website (https://​w ww.uspreventive​services​task​                          one year ago.
                                                                                    l D. She has inconsistent use of condoms with part-
  force.org). The practice recommendations in this activ-
  ity are available at https://​w ww.uspreventive​services​task​
  force.org/uspstf/recommendation/prevention-of-human-                                   ners whose HIV status is unknown.
  immunodeficiency-virus-hiv-infection-pre-exposure-                                l E. She reports no illicit substance use.
  prophylaxis.
  This series is coordinated by Joanna Drowos, DO, contrib-
  uting editor.
  A collection of Putting Prevention into Practice published in
  AFP is available at https://​w ww.aafp.org/afp/ppip.
  CME This clinical content conforms to AAFP criteria for CME.
  See CME Quiz on page 539.
  Author disclosure:​No relevant financial relationships.


Downloaded
December   from◆ the
         2023        American
                 Volume   108,Family
                               NumberPhysician
                                        6      website at www.aafp.org/afp.        © 2023 American Academy of Family
                                                                            Copyright
                                                             www.aafp.org/afp                                  American    Family
                                                                                                                      Physicians.     the private, 617
                                                                                                                                  ForPhysician     non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                       PUTTING PREVENTION INTO PRACTICE


3. According to the USPSTF recommendation statement,             HIV should also be considered for PrEP.1 People who engage
which of the following statements about the use of PrEP          in transactional sex (e.g., sex for money, drugs, or housing),
for the primary prevention of HIV in adults are correct?         including commercial sex workers or people trafficked for
  l A. Oral tenofovir disoproxil fumarate/emtricitabine          sex work, and transgender people should be considered
       (TDF/FTC) and injectable cabotegravir are                 based on the criteria from the recommendation statement.
       approved for use in at-risk adults and adolescents          3. The correct answers are A, C, and D. The U.S. Food
       to reduce the risk of sexually acquired HIV.
                                                                 and Drug Administration (FDA) has approved TDF/FTC
  l B. In people who inject drugs, oral TDF/FTC, oral            and injectable cabotegravir to reduce the risk of sexually
       tenofovir alafenamide/emtricitabine (TAF/FTC),            acquired HIV in at-risk adults and adolescents weighing at
       and injectable cabotegravir are approved for use
                                                                 least 35 kg. TAF/FTC is also approved by the FDA for use
       to reduce the risk of acquiring HIV via injection
       drug use.                                                 in at-risk adults and adolescents weighing at least 35 kg to
                                                                 reduce the risk of sexually acquired HIV, excluding individ-
  l C. Black people with an indication for PrEP are less
       likely to have received PrEP than White people
                                                                 uals at risk from receptive vaginal sex.1 No PrEP medications
       with an indication.                                       have received FDA approval for the indication of reducing
                                                                 HIV acquisition via injection drug use;​however, people
  l D. Eighty percent of new HIV diagnoses in the
       United States occur among adolescent and adult            who inject drugs and who have increased risk are likely to
       men.                                                      benefit from PrEP.1 Clinicians should note that barriers to
                                                                 and disparities in the initiation of PrEP exist;​the Centers for
                                                                 Disease Control and Prevention has estimated that the pro-
                                                                 portion of people with indications for PrEP who received it
Answers                                                          was 60.5% among White people vs. 7.9% in Black people and
1. The correct answer is B. The USPSTF recommends that           13.8% in Hispanic/Latino people.1,2 Additionally, of the more
clinicians prescribe PrEP using effective antiretroviral ther-   than 30,000 estimated new HIV cases diagnosed in 2020,
apy to those who are at increased risk to decrease the risk      80% occurred among adolescent and adult men, whereas
of acquiring HIV.1 The USPSTF does not recommend selec-          18% occurred among adolescent and adult women.1,3
tively prescribing PrEP to people with increased risk of HIV     The opinions and assertions expressed herein are those of the
or precluding PrEP for older adults. The USPSTF concludes        authors and do not reflect the official policy or position of the
that there is substantial net benefit from the use of PrEP to    U.S. Department of Health and Human Services, the Uniformed
reduce the risk of acquisition of HIV in people at increased     Services University of the Health Sciences, or the U.S. Depart-
                                                                 ment of Defense.
risk and recommends PrEP for adolescents (weighing at
least 35 kg [77 lb]) and adults at increased risk of HIV.        References
   2. The correct answer is D. The USPSTF recommends             1. Barry MJ, Nicholson WK, Silverstein M, et al. Preexposure prophylaxis
the following people be considered for PrEP:​sexually active        to prevent acquisition of HIV:​US Preventive Services Task Force recom-
                                                                    mendation statement. JAMA. 2023;​330(8):​736-745.
adults or adolescents who have engaged in anal or vaginal        2. Chou R, Spencer H, Bougatsos C, et al. Preexposure prophylaxis for the
sex in the past six months with a partner who has HIV;​had          prevention of HIV:​updated evidence report and systematic review for
a bacterial STI in the past six months;​or have inconsistently      the US Preventive Services Task Force. JAMA. 2023;​330(8):​746-763.
or not used condoms with sex partners whose HIV status is        3. Centers for Disease Control and Prevention. HIV surveillance report:
                                                                    diagnoses of HIV infection in the United States and dependent areas
unknown.1 People who inject drugs and share drug-injection          2020. Published May 2022. Accessed June 28, 2023. https://www.cdc.
equipment or who have a drug-injecting sex partner who has          gov/hiv/library/reports/hivsurveillance/vol-33/index.html ■




618 American Family Physician                       www.aafp.org/afp                          Volume 108, Number 6 ◆ December 2023
